Sustainability and equal access to health care for all is at risk due to rapidly increasing costs. The reasons for this are diverse: increased standard of living and life expectancy, but also the high cost of new drug innovations. Today’s society is looking for inexpensive solutions to its ever-increasing demands. Healthcare systems endeavour on the one hand to provide groundbreaking, novel solutions to a greater than ever demand for therapeutic assistance, and on the other hand to achieve this in the most cost-efficient way.
The availability of low-cost pharmaceutical products through generic medicines, and the ability to make medical care affordable to everyone are high on the social and political agenda of almost every nation in the world.
The Generics and Biosimilars Initiative (GaBI), founded by Professor Huub Schellekens, Professor Arnold Vulto, both from The Netherlands, and Ms Lasia Tang from Belgium, has been set up to support these demands.
GaBI provides an umbrella for a range of activities, such as an online news exchange platform, an independent peer reviewed journal, educational workshops and scientific conferences. The multifaceted characteristic of GaBI and its involvement in the scientific world under various forms will ensure the wide dissemination of its objectives.